Your browser doesn't support javascript.
loading
Psychometric Evaluation of the Diary for Irritable Bowel Syndrome Symptoms-Constipation in a Prospective Observational Study.
McLeod, Lori; Ervin, Claire; Fehnel, Sheri E; Eremenco, Sonya; Carson, Robyn T; Hanlon, Jennifer; Coons, Stephen Joel.
Afiliación
  • McLeod L; RTI Health Solutions, Research Triangle Park, NC, USA. Electronic address: lmcleod@rti.org.
  • Ervin C; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Fehnel SE; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Eremenco S; Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, USA.
  • Carson RT; Patient-Centered Outcomes Research, AbbVie, Madison, NJ, USA.
  • Hanlon J; IQVIA, Cambridge, MA, USA.
  • Coons SJ; Clinical Outcome Assessment Program, Critical Path Institute, Tucson, AZ, USA.
Value Health ; 27(5): 614-622, 2024 May.
Article en En | MEDLINE | ID: mdl-38311181
ABSTRACT

OBJECTIVES:

To evaluate the psychometric properties of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C), which was developed to support primary and secondary endpoints in irritable bowel syndrome (IBS) with predominant constipation (IBS-C) clinical trials.

METHODS:

Observational data were collected from 108 adults with IBS-C using a smartphone-type device for 17 days. DIBSS-C data regarding bowel movements (BMs) were collected for each event (along with the Bristol Stool Form Scale); abdominal symptoms were rated each evening. Global status items and the Gastrointestinal Symptom Rating Scale-IBS were completed on day 10 and day 17 and the IBS-Symptom Severity Scale on day 17. Item-level performance, internal consistency reliability, test-retest reliability, and construct validity were evaluated.

RESULTS:

The Abdominal Symptoms Domain score demonstrated high internal consistency reliability (Cronbach's alpha week 1 = 0.98; week 2 = 0.96) and test-retest reliability (intraclass correlation coefficient [ICC] = 0.93). Test-retest reliability was stronger for abdominal symptoms (ICC = 0.91-0.94) than for the frequency-based BM-related outcomes (ICC = 0.54-0.66). Key construct validity hypotheses were supported by moderate to strong correlations with the corresponding Gastrointestinal Symptom Rating Scale-IBS, IBS-Symptom Severity Scale, and Bristol Stool Form Scale items. All known-groups comparisons were statistically significant for the abdominal symptom items and domain score; evidence for known-groups validity of BM-related outcomes was supportive when based on constipation severity.

CONCLUSIONS:

The results of this study provided key psychometric evidence for the DIBSS-C, ultimately contributing to its qualification by the US Food and Drug Administration for use in IBS-C clinical trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psicometría / Índice de Severidad de la Enfermedad / Estreñimiento / Síndrome del Colon Irritable Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psicometría / Índice de Severidad de la Enfermedad / Estreñimiento / Síndrome del Colon Irritable Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2024 Tipo del documento: Article